Nabriva Therapeutics plc
Other OTCTotal Valuation
Nabriva Therapeutics plc carries a market capitalization of 323.00, placing it among publicly traded companies globally. Its enterprise value stands at -1.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 323.00 |
| Enterprise Value | -1.64M |
Share Statistics
Nabriva Therapeutics plc currently has 3.23M shares outstanding.
| Shares Outstanding | 3.23M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Nabriva Therapeutics plc maintains a current ratio of 0.38, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -3.31, indicating conservative leverage, while an interest coverage ratio of -103.58 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.38 |
| Quick Ratio | 0.25 |
| Debt / Equity | -3.31 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -103.58 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -168.18 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.41 |
Taxes
| Income Tax | 829,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Nabriva Therapeutics plc's stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Nabriva Therapeutics plc generated 29.39M in revenue and converted that into -55.05M in net income, yielding earnings per share of -18.02. EBITDA reached -49.61M, while operating income came in at -49.71M.
| Revenue | 29.39M |
| Gross Profit | -4.89M |
| Operating Income | -49.71M |
| Pretax Income | -54.22M |
| Net Income | -55.05M |
| EBITDA | -49.61M |
| EBIT | -49.71M |
| Earnings Per Share (EPS) | -18.02 |
Balance Sheet
Nabriva Therapeutics plc holds 2.18M in cash and equivalents against 540,000.00 in total debt, resulting in a net debt position of -1.64M. Total book value stands at -673.59M, with working capital of -16.25M providing operational flexibility.
| Cash & Cash Equivalents | 2.18M |
| Total Debt | 540,000.00 |
| Net Debt | -1.64M |
| Equity (Book Value) | -673.59M |
| Book Value Per Share | -220.49 |
| Working Capital | -16.25M |
Cash Flow
Nabriva Therapeutics plc produced -12.91M in operating cash flow over the past twelve months. After subtracting -115,000.00 in capital expenditures, free cash flow totaled -13.02M - equivalent to -4.26 per share.
| Operating Cash Flow | -12.91M |
| Capital Expenditures | -115,000.00 |
| Free Cash Flow | -13.02M |
| FCF Per Share | -4.26 |
Margins
Nabriva Therapeutics plc operates with a gross margin of -16.64, reflecting its pricing power and cost economics. The operating margin of -169.17 and net profit margin of -187.34 provide insight into operational efficiency.
| Gross Margin | -16.64 |
| Operating Margin | -169.17 |
| Pretax Margin | -184.52 |
| Profit Margin | -187.34 |
| EBITDA Margin | -168.83 |
Stock Splits
Nabriva Therapeutics plc's most recent stock split took place on September 16, 2022 with a 25:1 split ratio.
| Last Split Date | 9/16/2022 |
| Split Ratio | 25:1 |
Scores
Nabriva Therapeutics plc posts an Altman Z-Score of -103.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -103.74 |